Editor's Corner

  • The Fiercest 15 in med tech: send us your best bets

    Last year's Fierce 15 med tech winners include an implant maker for sinusitus that recently filed for an $80 million IPO, a fierce competitor to device giants Medtronic and Edwards Lifesciences in the emerging market for minimally invasive heart valves and a market leader in developing nerve-stimulating implant for rheumatoid arthritis and Crohn's disease. What will 2014 bring? That depends on you.

Upcoming study to dispute FDA's data on power morcellation risk

Dr. Elizabeth Pritts, director of the Wisconsin Fertility Institute, believes that the FDA is wildly overestimating the prevalence of uterine sarcoma in women undergoing hysterectomies and myomectomies for fibroid removal and worries that banning or restricting use of power morcellators will fail to address the problem, putting women undergoing the procedure at risk of upstaged cancer.

Bard is acquisition shopping--with $1B in cash and pressure from Medtronic/Covidien merger

The Medtronic merger with Covidien could offer a particular threat to C.R. Bard's vascular business--its largest segment and one of its fastest growing. The company was clear that it's actively in the market for its own strategic acquisitions; it hasn't disclosed a sizeable deal in almost a year.

St. Jude laying off up to 270 workers in California

The second shift at St. Jude Medical's cardiology device manufacturing facility in Sylmar, a suburb of Los Angeles, is being eliminated, resulting in the loss of up 270 jobs. The layoffs will take effect July 28, reports the San Fernando Valley Business Journal. 

Covidien is popping the bubbly for positive Q3 numbers

Covidien is celebrating third quarter earnings buoyed by strong sales, with its surgical solutions unit and progress in emerging markets generating an sizeable increase in cash flow.

Varian, AngioDynamics fall on earnings disappointments

Varian Medical Systems closed out a winning streak, while AngioDynamics deepened its losses when each company reported earnings for the second quarter.


From Our Sister Sites

FierceBiotech Research

In response to back-to-back incidents involving government laboratories, a top official at the U.S. Centers for Disease Control and Prevention has resigned, and the agency has assembled a safety board to address concerns that have arisen after workers were potentially exposed to anthrax and H5N1 flu.


Merck is going through a complete makeover, buying and selling units at a rapid pace. And some of its employees are getting caught in its "out with the old and in with the new" philosophy. Now 600 sales reps have been told their services are no longer needed